TerminatedPhase 2/3

Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms

Stopped: Primary Endpoint met

Ethiopia, Kenya, Mozambique1,001 participantsStarted 2022-01-20

Plain-language summary

The purpose of this clinical trial is to evaluate a fixed-dose co-formulation (FDC) of ivermectin and albendazole for the treatment of all Soil Transmitted helminths (STH). The current strategy to control STH in endemic areas is mass administration of albendazole or mebendazole, mainly to pre-school and school-aged children. Although this treatment works well for some STH species, efficacy against Trichuris trichiura is poor and it is not effective Strongyloides stercoralis. Thus new drugs or drug combinations are an urgent priority to increase the effectiveness of control programmes. Furthermore, the World Health Organisation has recommended combination therapy of ivermectin with albendazole. The trial proposed, is an adaptive phase II/III trial where the phase II component will evaluate the safety of the FDC as a single dose or 3-day single dose regimen for the treatment of T. trichiura in paediatric population. After analysis of the safety results the phase III trial will be executed to evaluate the efficacy of the FDC as a single dose or 3-day single dose regimen compared to the standard single dose regimen of ALB (400 mg) for the treatment of T. trichiura, hookworm and S. stercoralis in paediatric and young adult population. The estimated total sample size for the adaptive design (phase II and III component) is 1223 participants. Of these, 126 will be enrolled in the phase II and 1097 in the phase III components respectively in an adaptive trial design.

Who can participate

Age range5 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Positive infection test by microscopy for at least one of the following STH: T. trichiura, hookworms and/or larvae of S. stercoralis. * Weight ≥15 Kg. * Male or female, aged 5 to 18 years. * Female participants who are ≥12 years old (or female post menarche) must have a negative urine pregnancy test at screening or at the time of randomization. * Ability to take oral medication and willingness to comply with all study procedures. * Parental acceptance to participate in the study by obtaining a signed and dated informed consent form approved by the Regulatory authorities. In addition, verbal assent will be obtained from children aged 12-18 years. Exclusion Criteria: * Intake of ALB, mebendazole and/or IVM, or any potentially interacting drug three months before screening. * Residence outside the study area or planning to move away in the four weeks following recruitment. * Epidemiological risk of infection by Loa loa. * Serious medical illness, per investigator's criteria. * Any participant's condition that would prevent the appropriate evaluation and followup, as per investigator's criteria. * Known hypersensitivity to any components of either of the study treatment. * Positive pregnancy urine test, pregnant or first week postpartum.

What they're measuring

Cure Rate for T. Trichiura (CR)

Timeframe: 21 days

Frequency of Related Adverse Events

Timeframe: 21 days postreatment

Trial details

NCT IDNCT05124691

SponsorBarcelona Institute for Global Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-21

Results submitted2025-02-28